We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood-Based Methylation Assay Detects Colorectal Cancer

By LabMedica International staff writers
Posted on 24 Sep 2009
An on-going evaluation of a blood-based methylation assay for the screening and detection of colorectal cancer (CRC) has produced promising results. More...


The outcome of the evaluation was presented on September 21, 2009 at the 15th Congress of the European Cancer Organization and 34th Congress of the European Society for Medical Oncology in Berlin, Germany. Data on the method of methylation marker selection, the analytical performance of the test and the first results from a multi-center feasibility study was presented. The ultimate goal of the program was to provide a sensitive, specific, and patient-friendly option for colorectal cancer screening.

The blood-based methylation assay was developed by OncoMethylome (Liege, Belgium). Methylation is a natural control mechanism that regulates gene expression in DNA. Abnormal methylation of certain genes, such as tumor suppressor genes, can silence gene expression and is associated with cancer development. Genes, whose methylation is linked to cancer, are called methylation markers. OncoMethylome owns proprietary technology that is highly sensitive and capable of detecting methylation markers, and thereby cancer, even in early stages of cancer development.

"We optimized the methods of DNA extraction and methylation detection so that we could detect low levels of methylated genes in blood samples of people with colorectal cancer," says Dr. Louwagie, OncoMethylome's VP of product development, "and we were able to find a high frequency of two newly reported methylation genes, SYNE1 and FOXE1, in colorectal cancer patients. Equally important, the same methylation genes occurred infrequently in noncancerous individuals."

Once the test is validated, it will be a more acceptable alternative for those not wanting to undergo a colonoscopy or to do a fecal occult blood test (FOBT). More colorectal cancers will be discovered at an early stage of the disease.

Colorectal cancer (CRC) occurs in approximately one in every 17 people during their lifetime and is the second leading cause of cancer-related death in the United States and Europe, where a combined total of about 560,000 people develop the disease each year and 250,000 die from it. CRC typically occurs in adults (over age 50) but, because symptoms are often not present in early-stage disease, less than 40% of patients are diagnosed at an early stage when the disease is most treatable.

Colonoscopy, where the interior of the colon and rectum is examined using a tiny camera mounted on a flexible tube, is the most sensitive test currently available and has the benefit of allowing removal of precancerous polyps. Colonoscopy, however, is invasive, expensive, requires bowel preparation and skilled practitioners, thereby making it inaccessible or unacceptable for many patients.

Fecal occult blood testing (FOBT), where patients give stool samples to be analyzed, is less invasive than colonoscopies, inexpensive and is used in national screening programs in some European countries. This test detects the presence of blood in a stool sample, which can be due to CRC but also to other noncancerous conditions. Due to patients' reluctance to handle stool samples, compliance for even the best-organized national screening programs in Europe is often less than 50%. In the US, less than 20% of the targeted population undergoes FOBT screening within a two-year period.

Related Links:

OncoMethylome



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Specimen Radiography System
TrueView 200 Pro
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.